Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC

1 May 2024

Abstract excerpt

BACKGROUND: Transarterial chemoembolization is the first-line treatment for intermediate-stage HCC. However, the response rate to transarterial chemoembolization varies, and the molecular mechanisms underlying variable responses are poorly understood. Patient-derived hepatocellular carcinoma organoids (HCCOs) offer a novel platform to investigate the molecular mechanisms underlying doxorubicin resistance....

Topics

Join the communities discussing this publication.

Cancer Cells and Metastasis
Drug Transport and Resistance Mechanisms
Hepatocellular Carcinoma Treatment and Prognosis

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38696353
DOI: 10.1097/hc9.0000000000000437

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCCPMID 38696353Read ↗

NRF 2/ ABCB 1‐mediated efflux and PARP 1‐mediated dampening of DNA damage contribute to doxorubicin resistance in chronic hypoxic HepG2 cellsSemantic proximity Read ↗

The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cellsSemantic proximity Read ↗

Mechanisms of drug resistance in hepatocellular carcinomaSemantic proximity Read ↗

Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic AspectsSemantic proximity Read ↗

Radioresistance in Hepatocellular Carcinoma: Biological Bases and Therapeutic ImplicationsSemantic proximity Read ↗

Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localizationSemantic proximity Read ↗

Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy.Semantic proximity Read ↗

Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.Semantic proximity Read ↗

Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screenSemantic proximity Read ↗

Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes‐Associated Protein 1 Activation and Transient Expansion of Stem‐Like Cancer CellsSemantic proximity Read ↗

Histone deacetylase 2 regulates the doxorubicin (Dox) resistance of hepatocarcinoma cells and transcription of ABCB1Semantic proximity Read ↗

Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.